73 results about "Diaryl ether" patented technology

The present invention provides diaryl ether derivatives that exhibit significant immunosuppressive effects with less side effects.The diaryl derivatives of the present invention are represented by the following general formula (1): one example is 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propanediol.

A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed

The invention discloses a method for synthesizing asymmetric diaryl ether derivative with a structure shown in a structural formula (I), comprising the following steps: making arylboronic acid and nitrobenzene compound which are raw materials to fully react in an inert organic solvent in the presence of a copper catalyst, an additive and an alkaline compound at 30-150 DEG C, wherein the arylboronic acid has the structural formula (II), and the nitrobenzene compound has the structural formula (III); and postprocessing, separating and purifying a reaction solution after the reaction finishes to obtain the asymmetric diaryl ether derivative. The method for synthesizing the asymmetric diaryl ether derivative has the advantages of mild reaction condition, high reaction yield, good selectivity and low-cost generation cost.

The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

The invention discloses a 1-3 generation arylene ether-substituted dendritic phthalocyanine zinc complex, a preparation method and an application thereof. The method comprises the following steps of adopting a Frechet synthesis method to synthesize the first to third generation alcohol molecules which take the 1-3 generation cyan as an end group; leading the first to third generation alcohols to react with 4-nitrophthalonitrile respectively, thus synthesizing corresponding phthalocyanine precursor of dendrimer taking the 1-3 generation cyan as the end group; subsequently, leading the phthalocyanine precursor ring of dendrimer taking the 1-3 generation cyan as the end group to synthesize corresponding arylene ether dendritic phthalocyanine taking the first to third generation cyan as the end group and the arylene ether dendritic phthalocyanine taking the first to third generation carboxyl as the end group generated by hydrolysis. The 1-3 generation arylene ether dendritic phthalocyanine complex and the amphiphilic block copolymer are automatically dissolved to form the polymer nano-particle loading the 1-3 generation arylene ether dendritic phthalocyanine complex. The 1-3 generation diaryl ether dendritic phthalocyanine zinc complex and the loaded polymer nano-particle thereof are used as photosencitizers for photodynamic therapy.

One aspect of the present invention relates to novel reaction conditions that allow the efficient synthesis of diaryl ethers from arenes bearing a leaving group and arenols under relatively mild conditions. Another aspect of the present invention relates to the dramatic effects of acidic activators on Ullmann-type couplings involving electron-poor and / or relatively insoluble substrates.

The invention relates to an olefinic polymerization catalyst, a preparation method and a polymerization method. The olefinic polymerization catalyst comprises three components: A is solid catalyst component, B is organo-aluminum compound, and C is external electron donor and organic silicon compound; wherein, the A component contains titanium, magnesium and chlorine elements as well as internal electron donor which is the combination of 2, 4- diaryl acid pentanediol ester (PBA) and 1, 3-diether (BMF), the combination of the PBA and 1, 4- diaryl ether (BN), or the combination of PBA and aromatic acid ester. The olefinic polymerization catalyst has higher catalytic activity, the activity of the catalyst used for propylene polymerization can be regulated within the range of 40.0-120.0Kg pp / gCat, and isotactic index and molecular weight distribution index of polypropylene are also can be adjusted within the wide range.

Provided is a method for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a dehydration catalyst. The dehydration catalyst comprises an oxide of yttrium.

Provided is a process for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a dehydration catalyst. The dehydration catalyst is an oxide of a light rare earth element, wherein the light earth element is lanthanum, praseodymium, neodymium, or mixtures thereof.

Provided is a process for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a halogenated rare earth element oxide catalyst, providing a reaction vessel having loaded therein a rare earth element oxide; halogenating the rare earth element oxide with a halogen source to form an activated catalyst; and dehydrating an aromatic alcohol compound over the activated catalyst to form the diaryl ether compound, where the halogenating and dehydrating steps occur in the same vessel. The rare earth element oxide is an oxide of a light rare earth element, an oxide of a medium rare earth element, an oxide of a heavy rare earth element, an oxide of yttrium, or a mixture of two or more thereof.

Provided is a process for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a dehydration catalyst. The dehydration catalyst is an oxide of a heavy rare earth element, wherein the heavy rare earth element is terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, or mixtures thereof.

To provide a medicament which efficiently expresses an immunosuppressive agent or an anti-inflammatory agent and reduces expression of side effect.A medicament includes diaryl sulfide or diaryl ether compound having a 2-amino-1,3-propanediol structure having an activity of reducing lymphocytes circulating peripherally, in combination with an immunosuppressive agent and / or an anti-inflammatory agent.

Provided is a method for preparing a diaryl ether compound through the dehydration of an aromatic alcohol compound in the presence of a halogenated rare earth element oxide catalyst, wherein the used dehydration catalyst may be regenerated by a halogenation step. The rare earth element oxide is an oxide of a light rare earth element, an oxide of a medium rare earth element, an oxide of a heavy rare earth element, an oxide of yttrium, or a mixtures of two or more thereof.

Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders.